open access
Recent developments in diagnostics and monitoring of tyrosine kinase inhibitors treatment response of chronic myeloid leukemia
Affiliations- Klinika Hematologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie, Polska
open access
Abstract
Techniques of molecular biology are of key importance in diagnostics and monitoring of tyrosine kinase inhibitors (TKIs) treatment response of chronic myeloid leukemia (CML). Although much has already been achieved in this field, new prognostic factors and developments in laboratory methods are constantly emerging.
Halving time is a new prognostic factor defined as the rate of BCR-ABL1 decline from baseline, assessed by estimating the number of days over which BCR-ABL1 halved. Among patients with >10% BCR-ABL1 at 3 months of therapy with TKI, the poorest-risk group can be distinguished by the slow rate of BCR-ABL1 decline from baseline. More common use of techniques, such as the whole exome sequencing and transcriptome sequencing will enable assessment of patients’ genetic variation at diagnosis and may contribute to a prognostic score that will allow for optimization of therapy. Digital PCR built on traditional PCR provides highly sensitive absolute quantification of BCR-ABL1 transcript level without the need for standard curves and could further improve the treatment results in patients with CML.
Abstract
Techniques of molecular biology are of key importance in diagnostics and monitoring of tyrosine kinase inhibitors (TKIs) treatment response of chronic myeloid leukemia (CML). Although much has already been achieved in this field, new prognostic factors and developments in laboratory methods are constantly emerging.
Halving time is a new prognostic factor defined as the rate of BCR-ABL1 decline from baseline, assessed by estimating the number of days over which BCR-ABL1 halved. Among patients with >10% BCR-ABL1 at 3 months of therapy with TKI, the poorest-risk group can be distinguished by the slow rate of BCR-ABL1 decline from baseline. More common use of techniques, such as the whole exome sequencing and transcriptome sequencing will enable assessment of patients’ genetic variation at diagnosis and may contribute to a prognostic score that will allow for optimization of therapy. Digital PCR built on traditional PCR provides highly sensitive absolute quantification of BCR-ABL1 transcript level without the need for standard curves and could further improve the treatment results in patients with CML.
Keywords
CML; TKI; Halving time; Treatment response monitoring; Digital PCR
About this articleTitle
Recent developments in diagnostics and monitoring of tyrosine kinase inhibitors treatment response of chronic myeloid leukemia
Journal
Issue
Pages
121-127
Published online
2016-04-01
Page views
99
Article views/downloads
225
DOI
10.1016/j.achaem.2016.04.007
Bibliographic record
Acta Haematol Pol 2016;47(2):121-127.
Keywords
CML
TKI
Halving time
Treatment response monitoring
Digital PCR
Authors
Joanna Wącław
Tomasz Sacha